This Guidelines video has been commissioned and funded by Norgine Pharmaceuticals Limited and developed in partnership with Guidelines. Norgine Pharmaceuticals Limited suggested the topic for the video, worked with MGP Ltd to choose and commission the presenter, and reviewed and approved all materials related to the video. The views and opinions expressed in the video are not necessarily those of Norgine Pharmaceuticals Limited, or Guidelines, its publisher, advisers, or advertisers. Prescribing information can be found at the end of the video.

Click here for prescribing information

 

The IMPRESS study, published in April 2017, sheds light on the impact of rifaximin-α therapy on hospital resource utilisation for people with hepatic encephalopathy across several key resource parameters including hospital admissions, bed occupancy, emergency department attendances, and unplanned 30-day readmissions to hospital.

In this short video, Dr Richard Aspinall, Consultant Hepatologist at Portsmouth Hospitals NHS Trust and Joint Chief Investigator for the IMPRESS study, answers the following questions:

NORGINE and the sail logo are registered trademarks of the Norgine group of companies.

References

      1. Norgine Limited. TARGAXAN 550 mg film-coated tablets—summary of product characteristics. October 2016. www.medicines.org.uk/emc/medicine/27427
      2. Hudson M et al. Frontline Gastroenterology 2017; 0: 1–9.
      3. Tapper E et al. Clin Gastroenterol Hepatol 2016; 14 (8): 1181–1188.
      4. Hudson M et al. Poster presented at ISPOR Annual European Congress. 29 October–2 November 2016; Vienna. Poster number PGI10.

UK/XIF5/0717/0323cDate of preparation: March 2018